Halozyme Therapeutics, Inc. · NASDAQ:HALO
Halozyme Therapeutics — Investor Presentation (January 2005)
28 slides from Halozyme Therapeutics's investor presentation, Jan 28, 2005
Slide 1: Focus on Enhanced and Innovative Recombinant Human Enzymes
Focus on Enhanced and Innovative Recombinant Human Enzymes
Slide 2: Safe Harbor
Safe Harbor The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. All statements made in this presentation that are not statements of historical fact constitute forward-looking statements. The matters referred to in forward-looking statements c
Slide 3: Company Highlights
First and only recombinant human hyaluronidase (rHuPH20), synthetic form of animal-derived enzyme Robust near-term product developments and valuation drivers expected Development pipeline collectively addresses large therapeutic markets IP leadership position with six issued and four pending patents
Slide 4: Therapeutic Target for Recombinant Human Hyaluronidase (rHuPH20)
Hyaluronic acid (HA) is a space-filling, "gel"-like substance found in tissues throughout the body (e.g., skin, eyes) Hyaluronic Acid (HA) C C C C O C O N C O O R CH 2 OH OH NH CH3 C C C O C C C O OH O OH - - O OH + Hyaluronidase ß 1,4 Therapeutic Target for Recombinant Human Hyaluronidase (rHuPH20)
Slide 5: Competing Slaughterhouse Hyaluronidases Are Crude Extracts
Today's commercial enzymes extracted from cattle testes (typically <1-5% pure) Animal pathogen transmission risk Other contaminants Crude extracts may also cause allergic reactions to animal proteins Slaughterhouse manufacturing process is inefficient Problems Bovine Ovine Humanrec 100 U/lane PH20 H
Slide 6: Efficient, Scalable Manufacturing Process
INTERNAL: Up and downstream process development Formulation, stability, and assay development assay development assay development assay development assay development assay development EXTERNAL: Master cell banking Manufacturing QA/QC, fill finish 100L reactor 25L reactor Microgram/vial dose translat
Slide 7: Rich Product Pipeline
Product Target indication(s) Cumulase(tm) Infertility Enhanze SC(tm) Ophthalmology, neonatology, critical care, etc. Chemophase(tm) Oncology HTI-101 Inflammation, lysosomal storage disorders HTI-201 Inflammation, oncology HTI-401 Neurology, wound healing Research Pre- clinical Phase 1 & 2 Phase 3 Pr
Slide 8: Cumulase - Infertility
Ex vivo formulation used to remove cumulus matrix prior to certain in vitro fertilization (IVF) procedures Animal-derived PH20 extracts are the last animal-derived products used in entire IVF process Superior product to replace slaughterhouse-derived extracts: Increased potency, Decreased toxicity P
Slide 9: Cumulase: Enzyme Is Essential Component Of Process
PH20: Used to retrieve oocyte from cumulus during IVF/ART PH20: Used to retrieve oocyte from cumulus during IVF/ART oocyte Cumulus Oocyte after removal of cumulus Intracytoplasmic sperm injection (ICSI) Healthy embryo ready for implantation A. B. C. D. +PH20 Cumulase(tm): Enzyme Is Essential Compone
Slide 10: Enhanze SC - Ophthalmology and Drug Delivery
First product in the Enhanze(tm) Technology Platform Fast-acting, low dose, local formulation to enhance diffusion of anesthesia during ophthalmic surgery 50+ years clinical validation from Wyeth's Wydase(r): "Adjuvant to increase the absorption and dispersion of other injected drugs, for hypodermoc
Slide 11: Exclusive Sales & Marketing Agreement with Baxter Healthcare for Enhanze SC
Exclusive Sales & Marketing Agreement with Baxter Healthcare for Enhanze SC Baxter to market, distribute, and sell Enhanze SC(tm) in US and Puerto Rico; partners may mutually agree to pursue other territories Baxter and Halozyme are equal partners in commercialization of rHuPH20 Initial indication i
Slide 12: Enhanze SC for Ophthalmic Regional Anesthesia
Lidocaine Bupivacaine + Enhanze SC Enhanze SC(tm) for Ophthalmic Regional Anesthesia
Slide 13: Complete akinesia: Proceed with surgery
Complete akinesia: Proceed with surgery
Slide 14: Enhanze Technology Demo: Reduced Tissue Distortion and Pain
Control 2MIN rHuPH20 300ul/Min PBS Enhanze(tm) Technology Demo: Reduced Tissue Distortion and Pain
Slide 15: Enhanze Technology Demo: Reduced Tissue Distortion and Pain (Continued)
Saline + rHuPH20 Saline Enhanze(tm) Technology Demo: Reduced Tissue Distortion and Pain (Continued)
Slide 16: Enhanze Technology can Transform Other Injectable Drugs
Enhanze(tm) Technology can Transform Other Injectable Drugs Decrease pain and tissue distortion upon injection Reduce adverse injection site reactions Change route of administration (e.g., IV to SC) Convenience & compliance Extend product lifecycle of drugs coming off patent Provide differentiation
Slide 17: Example #1: Commercial Anti-Rheumatic Monoclonal Antibody
Example #1: Commercial Anti- Rheumatic Monoclonal Antibody
Slide 18: Example #2: Commercial Interferon
Example #2: Commercial Interferon
Slide 19: Chemophase - Oncology
Novel chemoadjuvant for treatment of solid tumors High dose formulation of rHuPH20 Under development to enhance delivery of systemically administered chemotherapy in patients with chemo-resistant tumors May renew response to chemotherapy regimens and potentially increase patient survival Applicable
Slide 20: Many Solid Tumors are Chemo-resistant Because Chemo Can't Reach Tumor Cells
Many Solid Tumors are Chemo-resistant Because Chemo Can't Reach Tumor Cells Chemotherapy agent Diffusion is rate-limiting factor for many chemo- therapeutics, resulting in chemo- resistance
Slide 21: Chemophase Can Enhance Effectiveness of Chemotherapy Agents
Chemotherapy agent Chemophase Chemophase(tm) Can Enhance Effectiveness of Chemotherapy Agents Chemophase increases tumor bioavailability in chemo- resistant solid tumors
Slide 22: External Clinical Studies of Bovine IV PH20 Yield Promising Results
Source: G. Baumgartner, et. al., Cancer Letters 131 (1998) External Clinical Studies of Bovine IV PH20 Yield Promising Results in Multiple Solid Tumors
Slide 23: Brain Tumor Studies
Brain Tumor Studies Increased Survival Demonstrated in Pediatric Patients with Brain Tumors
Slide 24: Market Opportunities
Product Indications Market opportunity Cumulase(tm) Infertility $10 million Ophthalmic anesthesia $50 - 100 million Enhanze SC(tm) Other Wydase(r) applications $200 - 300 million Chemophase(tm) Oncology chemo-adjuvant $600 - 800 million Market Opportunities
Slide 25: Milestone-Driven, Capital-Efficient Business Model
Milestone-Driven, Capital-Efficient Business Model Completed Q4 Q1 Q2 Q3 Q4 Q1 Q2 2004 2005 rHuPH20 purification/validation Master cell banking Cell line engineering Manufacturing and fill/finish Cumulase lot release Enhanze SC lot release Cumulase 510(k) process CE Mark clearance Product launch Enh
Slide 26: Financial Summary
Cash position as of Q4 2004 - $16.0 million Potential proceeds from warrants - $18.5 million Market capitalization - $90 million as of 1/25/05 49.2 million shares outstanding Financial Summary
Slide 27: Company Highlights
First and only recombinant human hyaluronidase (rHuPH20), synthetic form of animal-derived enzyme Robust near-term product developments and valuation drivers expected Development pipeline collectively addresses large therapeutic markets IP leadership position with six issued and four pending patents
Slide 28: Focus on Enhanced and Innovative Recombinant Human Enzymes
Focus on Enhanced and Innovative Recombinant Human Enzymes
Halozyme Therapeutics — Investor Presentation (January 2005) on 6ix